Synmabtix is a biotechnology company developing antibody-based drugs directed against certain toll like receptors to decrease chronic inflammation in rheumatoid arthritis and potentially other chronic inflammatory diseases


Yvo Graus, PhD MBA
M’hamed Hadfoune, Bsc
Leo Joosten, PhD

CEO and co-founder

Yvo Graus is a biotech professional with extensive experience in pre-clinical development of antibody-based therapeutics for the treatment of cancer. He previously served as Vice President Pre-clinical Operations at Genmab and was responsible for the pre-clinical development of several antibody discovery programs including darzalex. Before joining Genmab he was Head of Immunology Research at Numico Research, Wageningen.
He holds a MSc in Medical Biology from University of Amsterdam, a PhD in Molecular Immunology from Maastricht University and a MBA from Businesschool Nederland.

CTO and co-founder

M’hamed Hadfoune is an expert in hybridoma technology and has developed 40+ monoloclonal and polyclonal diagnostic/research antibodies which are currently being commercialized. He is manager of the immunology lab of the Surgery Department of MUMC+ and has broad experience in the field of microbiology, immunology and in vivomodels. He holds a BSc degree in Applied Sciences from Fontys Hogeschool Eindhoven.

CSO and co-founder

Leo Joosten is Professor of Mechanisms of Inflammatory Disease and Head of Experimental Medicine Lab, Radboud University Medical Center Nijmegen. He is world expert in pathogenic mechanism of rheumatoid arthritis, gout and lyme disease and specialized in Toll Like Receptor Biology. He is author of >420 scientific papers and co-inventor on 5 patents. He holds a PhD from Radboud University. 


Mihai Netea, MD, PhD
Steven WM Olde Damink,
Kaatje Lenaerts, PhD

Scientific Advisor and co-founder

Mihai Netea is Professor of Experimental Medicine at Radboud University Medical Center and world expert in innate immunity and has a broad expertise on the host mechanisms responsible for the recognition of bacterial and fungal pathogens and the activation of the innate immune system and the genetic susceptibility to infections. He holds a MD form the University of Medicine and Pharmacy of Cluj-Napoca, Romania and a PhD form Radboud University Nijmegen. He is author of >623 scientific papers and co-inventor of 5 patents and received the prestigious Spinoza Prize in 2016.

Scientific Advisor and co-founder

Steven Olde Damink is full Professor of Surgery at the Maastricht University Medical Center and the RWTH, Aachen, Germany. He is Head of the division of Liver & Digestive Health at the NUTRIM Research School, Maastricht University and an expert in Translational Research in Gastrointestinal Surgery, with specific focus on the Gut-Liver axis. He is author of >175 scientific publications and is co-inventor of 3 patents. He holds an MSc in Health Science and an MD, PhD in Medicine from Maastricht University and is AMP194 graduate of Harvard Business School.

Scientific Advisor and co-founder

Kaatje Lenaerts is Associate Professor, Department of Surgery, NUTRIM Research School of Nutrition and Translational Research in Metabolism of MUMC+ and scientific expert in o.a. gastro-intestinal innate immunity.  She is author of > 50 scientific publications and holds a MSc from Antwerp University and a PhD from Maastricht University.

Research & Development

Chantal van Heugten

Research Technician

© 2018 Synmabtix, all rights reserved
Design by Brightlands Maastricht Health Campus 

Oxfordlaan 70 

6229EV Maastricht 

The Netherlands